Xiangmin Cui

Dr. Xiangmin Cui is the Founder and serves as Managing Director at Decheng Capital. He is a Board Member at VelosBio. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and focused on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of GenapSys, GeneWeave Biosciences, Ketai Medical, Shenzhen GeneMDx Biotechnology, Accuragen and Sinomed. His investment portfolio also includes Ion Torrent Systems (acquired by Life Technologies for $725M), GenturaDx (acquired by Luminex), China Biologic Products (NASDAQ: CBPO), Epizyme (NASDAQ: EPZM), and Sunesis (NASDAQ: SNSS). Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University. He also serves as the Board Member at EpimAb Biotherapeutics.